Seventy-five percent of patients achieved a best response of bone marrow-undetectable measurable residual disease remission<\/p>\n<\/h3>\n
<\/b><\/p>\n
<\/b><\/p>\n
WEDNESDAY, June 23, 2021 (HealthDay News) — Combination therapy with ibrutinib and venetoclax seems beneficial for patients with previously untreated chronic lymphocytic leukemia (CLL), according to a study published online June 10 in JAMA Oncology<\/em>.<\/p>\n Nitin Jain, M.D., from the University of Texas MD Anderson Cancer Center in Houston, and colleagues enrolled 80 previously untreated patients with CLL in a single-center, phase 2 nonrandomized trial. Treatment consisted of ibrutinib monotherapy for three cycles, thereafter combined with venetoclax for a total of 24 cycles of combination treatment. Patients were followed for a median of 38.5 months.<\/p>\n Five of the patients discontinued the study during the monotherapy phase, and 75 received combination therapy. The researchers found that 56 and 66 percent of patients achieved bone marrow-undetectable measurable residual disease (U-MRD) remission at 12 and 24 cycles, respectively, on an intent-to-treat analysis of combined treatment. Seventy-five percent of patients achieved a best response of bone marrow U-MRD remission. Across all high-risk subgroups, responses were observed, independent of immunoglobulin heavy-chain variable gene mutation status, fluorescence in situ hybridization category, or TP53<\/em> mutation. Three-year progression-free and overall survival was 93 and 96 percent, respectively. None of the patients had CLL progression.<\/p>\n “I think this will be one of several standard of care treatments available for patients with CLL,” Jain said in a statement. “There are pros and cons to each of those approaches, and physicians will have to decide which option is best for their patient.”<\/p>\n Several authors disclosed financial ties to pharmaceutical companies, including AbbVie, which provided funding and supplied venetoclax.<\/p>\n Abstract\/Full Text (subscription or payment may be required)<\/a><\/p>\n <\/i><\/p>\n